Sareum Holdings plc

(“Sareum” or the “Company”)

Sareum to Present at BioTrinity 2021 Conference

Cambridge, UK, 21 June 2021 – Sareum Holdings plc (AIM: SAR), the specialist drug development company, announces that its CEO, Dr Tim Mitchell, will give a company presentation at 10:30am BST today at the BioTrinity 2021 conference.

In his presentation, Dr Mitchell will showcase Sareum’s two proprietary TYK2/JAK1 kinase inhibitor programmes: SDC-1801 targeting autoimmune diseases and the severe inflammatory responses and respiratory symptoms arising from Covid-19 and other viral infections, and SDC-1802 targeting cancers.

The presentation is available to delegates of BioTrinity 2021, and a copy of the slides will be made publicly available on Sareum’s website after the presentation - www.sareum.com

About BioTrinity

BioTrinity is a highly regarded biopartnering & investment life sciences conference, that aims to shine a light on new innovation in the life sciences industry and inspire growth and create opportunities for all who attend.

The 2021 event will be delivered in a true hybrid format, and will provide seamless live interaction for delegates, who include early-stage and emerging biotech, medtech and digital health companies, big pharma executives, life sciences investors and service providers.

BioTrinity 2021 will be delivered live in a hybrid format at etc. venues Bishopsgate, London and via a dedicated virtual platform on Monday 21 & Tuesday 22 June in person, with the virtual platform available until Friday 25 June. For more information on the BioTrinity event, please visit www.biotrinity.com.

For further information, please contact: 

Sareum Holdings plc

Tim Mitchell, CEO

 

 

01223 497 700

Strand Hanson Limited (Nominated Adviser)

James Dance / James Bellman

 

 

020 7409 3494

Hybridan LLP (Nominated Broker)

Claire Noyce

 

 

020 3764 2341

MEDiSTRAVA Consulting (Financial PR)

Mark Swallow/ David Dible

 

020 7638 9571

About Sareum

Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.

Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the ‘cytokine storm’ immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).

Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms. Preliminary Phase 2 and comprehensive preclinical data suggest SRA737 may have broad application in combination with other oncology and immune-oncology drugs in genetically defined patients.

SRA737 was discovered and initially developed by scientists at The Institute of Cancer Research in collaboration with Sareum, and with funding from Sareum and Cancer Research UK. SRA737 was licensed by CRT Pioneer Fund (CPF) to Sierra Oncology Inc. Sierra continues to explore options that would enable the development of SRA737 to advance.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company’s website at www.sareum.com

- Ends -

 

  • @Sareumplc Latest tweet

    RT @HybridanLLP: Good to see Sareum's research on TYK2 as an oncology target referenced here. We see Sareum as a frontrunner in this space… via @Sareumplc
    View more